Press Releases Ensurge Micropower ASA – Grant of Incentive Subscription Rights November 20, 2023 Share FacebookTwitterPinterestWhatsApp Must read Nvidia CEO aiming to set up base in Vietnam, Reuters reports December 10, 2023 Utz Brands to host investor day December 10, 2023 Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term... December 10, 2023 Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral... December 10, 2023 Ensurge Micropower ASA – Grant of Incentive Subscription Rights Source link Share FacebookTwitterPinterestWhatsApp Previous articleBuy Rating for Biohaven Ltd.: Promising Developments in BHV-1300 and BHV-7000 Programs and Potential Offset of Operating ExpensesNext articleRiding the Waves: Dollar Falls Amidst Market Turbulence More articles Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term... December 10, 2023 Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral... December 10, 2023 Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 December 10, 2023 Latest article Nvidia CEO aiming to set up base in Vietnam, Reuters reports December 10, 2023 Utz Brands to host investor day December 10, 2023 Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term... December 10, 2023 Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral... December 10, 2023 Autolus Therapeutics presents clinical data updates at ASH Annual Meeting 2023 December 10, 2023